Standout Papers
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (2020)
- Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials (2021)
Immediate Impact
3 by Nobel laureates 5 from Science/Nature 61 standout
Citing Papers
From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
Works of Hongxing Pan being referenced
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
2020 Standout
A Novel Influenza A (H1N1) Vaccine in Various Age Groups
2009
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Hongxing Pan | 1320 | 481 | 410 | 35 | 1.7k | |
| Kai Chu | 1386 | 406 | 272 | 47 | 1.8k | |
| Colin Campbell | 1697 | 581 | 378 | 42 | 2.2k | |
| Amadea Britton | 918 | 418 | 509 | 23 | 1.4k | |
| Abdullah Algaissi | 1241 | 174 | 189 | 44 | 1.7k | |
| Victoria Indenbaum | 1671 | 410 | 106 | 51 | 1.9k | |
| Neta S. Zuckerman | 1191 | 250 | 170 | 71 | 1.9k | |
| Weidong Yin | 1748 | 474 | 289 | 30 | 2.4k | |
| Katia Bruxvoort | 730 | 315 | 455 | 101 | 1.8k | |
| Yaling Hu | 1436 | 452 | 94 | 20 | 1.6k | |
| Sarah E. Wilson | 815 | 635 | 549 | 79 | 1.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...